Ellagic-acid (Quercetin-C), veel voorkomend in bessen, rode vruchten en noten geeft significant minder bijwerkingen en significant betere respons wanneer aanvullend gegeven bij chemokuren voor recidief van hormoonresistente prostaatkankerpatiënten blijkt

30 mei 2011: ik ben kanker-actueel aan het herzien en kwam deze studie naar effect van ellagic acid bij hormoonresistente prostaatkanker tegen. Met mooie therapeutische resultaten. Onderaan heb ik het volledige studieverslag toegevoegd van een overzichtstudie uit 2009 van het effect van de granaatappel bij prostaatkanker. Wetenschappers gaan ervan uit dat de ellagic acid uit de granaatappel verantwoordelijk is voor het positieve effect. Scroll naar onderen voor het studieverslag.

29 april 2005: Bron: Eur Urol. 2005 Apr;47(4):449-54;

Hoewel voor prostaatkanker zelden chemo wordt gegeven, alleen als alle andere behandelingen hun werking hebben verloren, blijkt uit gerandomiseerde fase III studie dat wanneer aanvullend ellagic acid gegeven wodt naast de chemokuren vinorelbine en estramustine phosphate bij hormoon resistente prostaatkankerpatiënten de algemene respons, dus aanslaan van de behandeling significant groter is dan wanneer alleen chemo wordt gegeven en ook de bijwerkingen, o.a. zenuwpijnen, en kwaliteit van leven zijn significant beter met de aanvullende ellegic acid dan bij alleen chemo. Op de uiteindelijke overleving werd geen significant verschil gevonden, hoewel ook hier een verbetering voor de ellagic acid groep werd gevonden maar niet significant. Lees toch ook eens andere artikel over ellagic acid waar tientallen studies vermeld staan over gunstige werking van ellegagic acid bij veel verschillende soorten kanker, zoals o.a. eierstokkanker en blaaskanker en borstkanker.Je kunt je natuurlijk afvragen of er geen studie gedaan zou moeten worden met alleen Ellagic Acid naast bv. hormoontherapie bij prostaatkankerpatiënten of dan de resultaten misschien zelfs beter zouden zijn.

Eur Urol. 2005 Apr;47(4):449-54;

Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate.

Falsaperla M, Morgia G, Tartarone A, Ardito R, Romano G. Operative Unit of Urology, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Potenza, Italy. mayurol@yahoo.it BACKGROUND: Recent phase III studies in hormone refractory prostate cancer (HRPC) showed an improvement in terms of overall survival (OS), objective response (OR) and biochemical response (BR); however, chemotherapy is usually accompanied by negative side effects that determines poor quality of life (QoL) and only marginally improves individual clinical response (ICR) in terms of pain relief and performance status. Ellagic acid is a polyphenol that is found in many species of flowering plants. It is an antioxidant that determines apoptosis, down regulation of IGF-II, activates p21 (waf1/Cip1), mediates the cumulative effect on G1/S transition phase and prevents destruction of p-53 gene by cancer cells.

ENDPOINTS: The aim of this study was to assess the effects of ellagic acid support therapy on toxicity, OR, ICR and BR in HRPC patients treated with estramustine phosphate and vinorelbine.

MATERIALS AND METHODS: Patients with HRPC were randomly distributed in two study groups: a control group (group A) who underwent chemotherapy with vinorelbine and estramustine phosphate, and an experimental group (group B) where chemotherapy regimen was associated with ellagic acid.

RESULTS: The mean number of chemotherapy cycles/patient was 4 (range 3-8 cycles) and 6.5 (range 5-11) in group A and B patients, respectively. A reduction in systemic toxicity, statistically significant for neutropenia, associated with better results in term of OR rate, ICR, and BR were observed in group B compared with group A. On the contrary no significant difference in OS and PFS was detected between groups.

CONCLUSIONS: our study suggests that the use of ellagic acid as support therapy reduces chemotherapy induced toxicity, in particular neutropenia, in HRCP patients; however, further studies are required to confirm our results.

PMID: 15774240 [PubMed - in process]

Cancer Chemoprevention by Pomegranate: Laboratory and Clinical Evidence

Vaqar Mustafa Adhami, Naghma Khan, and Hasan Mukhtar

Department of Dermatology, University of Wisconsin-Madison, Madison, Wisconsin, USA

Address correspondence to Hasan Mukhtar, Helfaer Professor of Cancer Research, Director and Vice Chair for Research, Department of Dermatology, University of Wisconsin, 1300 University Avenue, Medical Sciences Center, Room B-25, Madison, WI 53706. Phone: 608-263-3927. Fax: 608-263-5223. Email: hmukhtar@wisc.edu

Abstract

Pomegranate fruit from the tree Punica granatum has been dubbed as the “nature’s power fruit.” Dating back to Biblical times, the tree itself is attributed to possess extraordinary medicinal properties. The geographical distribution of the tree, being native to the Middle East and some Asian countries, is generally attributed to a lack of interest in its medicinal properties by many western scientists. However, the unique biochemical composition of the pomegranate fruit being rich in antioxidant tannins and flavonoids has recently drawn attention of many investigators to study its exceptional healing qualities. Recent research has shown that pomegranate extracts selectively inhibit the growth of breast, prostate, colon and lung cancer cells in culture. In preclinical animal studies, oral consumption of pomegranate extract inhibited growth of lung, skin, colon and prostate tumors. An initial phase II clinical trial of pomegranate juice in patients with prostate cancer reported significant prolongation of prostate specific antigen doubling time. This review focuses on recent investigations into the effects of pomegranate fruit on cancer.

INTRODUCTION

The fruit of the tree Punica granatum, grown mainly in the Mediterranean region, has been shown to possess many medicinal properties such as being antioxidant and anti-inflammatory (). The antioxidant activity of flavonoids obtained from pomegranate juice (PJ) was observed to be close to that of butylated hydroxyanisole, green tea, and significantly greater than red wine (,). Commercially available pomegranate juices tested for their antioxidant activity by the Trolox Equivalent Antioxidant Capacity (TEAC) assay showed antioxidant activity of ~18 to 20 TEAC that was three times higher than those of red wine and green tea (– TEAC). Interestingly, the antioxidant activity was higher in commercial juices that were extracted from whole pomegranates than in experimental juices that were obtained from the arils only (). Antioxidant activities of freeze-dried preparations of pomegranate and its 3 major anthocyanidins (delphinidin, cyanidin, and pelargonidin) were evaluated by Noda et al. () by the method of electron spin resonance technique and spin trapping. Pomegranate extract exhibited scavenging activity against OH and equation M1

. The anthocyanidins were found to inhibit a Fenton reagent ⁻OH generating system possibly by chelating with ferrous ion. Also, anthocyanidins scavenged equation M2

in a dose-dependent manner, and ID₅₀ values of delphinidin, cyanidin, and pelargonidin were 2.4, 22, and 456 µM, respectively. Anthocyanidins inhibited H₂O₂-induced lipid peroxidation in the rat brain homogenates and ID₅₀ values of delphinidin, cyanidin, and pelargonidin were 0.7, 3.5, and 85 µM, respectively (). Pomegranates have only recently been studied for their anticancer effects (Table 1). The following sections will summarize the studies on the effects of pomegranate against various cancers.

Read more>>>>>>>>

prostaatkanker, Ellagic-acid